Home
Rusan Pharma

Rusan Pharma Market Share Analysis for August 2026

Buy Naltrexone Hydrochloride Anhydrous (CAS 16676-29-2) from Rusan Pharma — cGMP & EDQM-certified. Ph. Eur. grade. DMF available. Suitable for oral and implant de-addiction formulations.

Health > Biotechnology and Pharmaceuticals

Domainrusanpharma.com

Year Founded1994

Employees501 - 1000

Annual Revenue$25M - $50M

Rusan Pharma

Rusan Pharma (including company regionals)

rusanpharma.com

See more website traffic and engagement information

Rusan Pharma Revenue up to August 2026 is 25M - 50M

revenue generated by Rusan Pharma top domains

Rusan Pharma top domains revenue over 3 years

Revenue for Rusan Pharma top domains

rusanpharma.com25M - 50M

See more with Sales Intelligence

Total visits to Rusan Pharma's top domains

Understand Rusan Pharma market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

rusanpharma.com9.3K

See more with Sales Intelligence

Avg. visit duration in Rusan Pharma's top domains

Analyze Rusan Pharma engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

rusanpharma.com00:00:34

See more with Sales Intelligence

Avg. pageviews on Rusan Pharma's top domains

See how Rusan Pharma keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

rusanpharma.com1.96

See more with Sales Intelligence

Rusan Pharma top competitors by domain

Top similar sites in August 2026, ranked by their affinity

intaspharma.comCompany NameIntas PharmaceuticalsEmployees> 10001HQIndia, AhmedabadAnnual revenue> $1BTotal visits115KHealth > Pharmacy

Top technologies used by Rusan Pharma

These are the website technologies, by industry, used by Rusan Pharma top domains

Widget (6)

reCAPTCHA

eCommerce (3)

WooCommerce

Payment & Currencies (3)

Cart Functionality

Email Services (2)

G Suite

More Technologies

11

See all

News & Signals from Rusan Pharma

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsRusan Pharma Limited expanded facilities to India, Southern Asia, Asia on Sep 3rd '26.Rusan Pharma plans to invest ₹200 crore to expand tablet and injectable manufacturing capacity at its Kandla Unit 1 facility in Gujarat, as the drugmaker estimates and estimates a ₹20,000-25,000-crore addiction-treatment market over the next three to four years.

NewsRusan Pharma Ltd is developing Eflornithine Hydrochloride Monohydrate on Jul 16th '26.As healthcare providers seek safer and more effective solutions, Rusan Pharma stands at the forefront of developing compounds like Eflornithine Hydrochloride Monohydrate that demonstrate how scientific innovation can improve patient care and expand therapeutic possibilities.

NewsRusan Pharma Ltd invests into assets: manufacturing infrastructure.Looking ahead, Rusan Pharma continues to invest in upgrading its manufacturing infrastructure, strengthening quality systems, and enhancing regulatory readiness.